scispace - formally typeset
Journal ArticleDOI

Mutant p53 as a target for cancer treatment.

Reads0
Chats0
TLDR
It remains to be shown however, whether any mutant p53 reactivating compound has efficacy for the treatment of human cancer.
About
This article is published in European Journal of Cancer.The article was published on 2017-09-01. It has received 246 citations till now. The article focuses on the topics: Cancer.

read more

Citations
More filters
Journal ArticleDOI

Ferroptosis: mechanisms and links with diseases.

TL;DR: Ferroptosis is an iron-dependent cell death, which is different from apoptosis, necrosis, autophagy, and other forms of cell death as discussed by the authors, which can be prevented by iron chelators and small lipophilic antioxidants (e.g., deferiprone, deferoxamine) and small iron-rich antioxidants such as ferrostatin, liproxstatin.
Journal ArticleDOI

Targeting Transcription Factors for Cancer Treatment.

TL;DR: Various ways to target transcription factors in cancer models are discussed: by modulating their expression or degradation, by blocking protein/protein interactions, by targeting the transcription factor itself to prevent its DNA binding either through a binding pocket or at the DNA-interacting site, some of these inhibitors being currently used or evaluated for cancer treatment.
Journal ArticleDOI

The p53 Pathway in Glioblastoma.

TL;DR: TP53 mutations in GBM are mostly point mutations that lead to a high expression of a gain of function (GOF) oncogenic variants of the p53 protein, which promote GBM malignancy.
Journal ArticleDOI

Noncoding RNAs in disease

TL;DR: A selection of studies are highlighted in order to demonstrate the wide‐scale involvement of miRNAs and long noncoding RNAs in the pathophysiology of three types of diseases: cancer, cardiovascular and neurological disorders.
Journal ArticleDOI

Targeting p53 for the treatment of cancer.

TL;DR: Should any of the compounds currently being evaluated in clinical trials be shown to have efficacy, it is likely to usher in a new era in cancer treatment, especially as p53 dysfunction is so prevalent in human cancers.
References
More filters
Journal ArticleDOI

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt, +355 more
- 04 Oct 2012 - 
TL;DR: The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity.
Journal ArticleDOI

Integrated genomic analyses of ovarian carcinoma

Debra A. Bell, +285 more
- 30 Jun 2011 - 
TL;DR: It is reported that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1,BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes.

Integrated genomic analyses of ovarian carcinoma

Daphne W. Bell, +261 more
TL;DR: The Cancer Genome Atlas project has analyzed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours as mentioned in this paper.
Journal ArticleDOI

Mutational landscape and significance across 12 major cancer types

TL;DR: Data and analytical results for point mutations and small insertions/deletions from 3,281 tumours across 12 tumour types are presented as part of the TCGA Pan-Cancer effort, and clinical association analysis identifies genes having a significant effect on survival.
Journal ArticleDOI

Comprehensive genomic characterization of squamous cell lung cancers

Peter S. Hammerman, +345 more
- 27 Sep 2012 - 
TL;DR: It is shown that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour.
Related Papers (5)